Nifedipine and cancer mortality: Ten-year follow-up of 2607 patients after acute myocardial infarction

Michael Jonas, Uri Goldbourt, Valentina Boyko, Lori Mandelzweig, Solomon Behar, Henrietta Reicher-Reiss*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Recent publications contended that the use of short-acting calcium antagonists may double the risk of cancer incidence and possibly increase mortality in hypertensive patients. The purpose of this study was to assess the risk ratio for cancer mortality associated with nifedipine in a large population of patients post-myocardial infarction. Cancer mortality data, over a 10-year period, were obtained on 2607 hospital survivors of acute myocardial infarction who were screened, but not included, in the Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT I) study. In this group of patients, 526 (20%) were on nifedipine, according to their treating physicians' decision. In the cohort of screened patients not included in SPRINT I, there were 22 (4.2%) cancer-related deaths in the patients on nifedipine compared with 114 (5.5%) in the group not treated with nifedipine (P = 0.23). In multivariate analysis, the 10-year cancer mortality risk ratio associated with nifedipine therapy was 1.06 (95% Cl 0.52-2.18). The current analysis shows no evidence of an increased risk of cancer mortality in a large number of patients treated at baseline with nifedipine.

Original languageEnglish
Pages (from-to)177-181
Number of pages5
JournalCardiovascular Drugs and Therapy
Issue number2
StatePublished - 1998


  • Calcium channel blockers
  • Cancer
  • Myocardial infarction
  • Nifedipine


Dive into the research topics of 'Nifedipine and cancer mortality: Ten-year follow-up of 2607 patients after acute myocardial infarction'. Together they form a unique fingerprint.

Cite this